SCHEDULE 2Relief for research and development: subjects of clinical trials
Amendments to Schedule 13 to FA 2002
3
(1)
Schedule 13 to FA 2002 (tax relief for expenditure on vaccine research etc) is amended as follows.
(2)
In paragraph 3 (qualifying expenditure on direct research and development), in sub-paragraph (5)—
(a)
omit the word “or” at the end of paragraph (b);
(b)
“(ba)
is incurred on relevant payments to the subjects of a clinical trial, or”.
(3)
In paragraph 5 (which applies certain definitions from Schedule 20 to FA 2000)—
(a)
in the heading, after “ “software or consumable items”,” insert “
“relevant payments to the subjects of a clinical trial”,
”
;
(b)
“(ca)
paragraph 6A (relevant payments to subjects of clinical trials);”.
(4)
In paragraph 9 (relevant expenditure of the sub-contractor), in sub-paragraph (3)—
(a)
omit the word “or” at the end of paragraph (b);
(b)
“(ba)
is incurred on relevant payments to the subjects of a clinical trial, or”.